{"entity":{"id":"martin-reck","kind":"person","name":"Martin Reck","aka":[],"tldr":"Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer.","summary":"Martin Reck (LungenClinic Grosshansdorf, Germany) was principal investigator of KEYNOTE-024, which showed pembrolizumab beats platinum chemotherapy in NSCLC with PD-L1 of 50% or more, the first time a checkpoint inhibitor replaced chemotherapy first line. He has led IMpower150 and numerous SCLC immunotherapy trials and has chaired ESMO's lung cancer guideline group.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reck%20M%5BAuthor%5D%20pembrolizumab%20lung"}],"tags":["lung","immunotherapy","trialist"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab","atezolizumab"],"companies":[],"institutions":["lungenclinic-grosshansdorf"],"pathways":[],"terms":[],"trials":["keynote-024-189"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Thoracic Oncology, LungenClinic Grosshansdorf","institutionId":"lungenclinic-grosshansdorf","specialisms":["Lung cancer immunotherapy","First-line NSCLC therapy","Small-cell lung cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Reck%20M%5BAuthor%5D%20pembrolizumab%20lung"}],"papers":[{"title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (KEYNOTE-024)","journal":"NEJM","year":2016,"doi":"10.1056/NEJMoa1606774"},{"title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.00174"}]},"route":"/people/martin-reck/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"lungenclinic-grosshansdorf","kind":"institution","name":"LungenClinic Grosshansdorf","route":"/institutions/lungenclinic-grosshansdorf/"},{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/"}],"trial":[{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/"},{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/"}],"paper":[{"id":"paper-checkmate-026-first-line-nivolumab-nejm-2017","kind":"paper","name":"CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer","route":"/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/"},{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/"},{"id":"paper-keynote-024-nejm-2016","kind":"paper","name":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer","route":"/key-papers/paper-keynote-024-nejm-2016/"},{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/"},{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/"}]}}